DelMar Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent for VAL-083

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 3, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 13/933,751, covering improved methods for synthesizing VAL-083, DelMar's lead drug candidate, which is currently in a Phase I/II clinical trial in the United States for the treatment of refractory glioblastoma multiforme (GBM). This patent is entitled "Method of Synthesis of Substituted Hexitols Such as Dianydrogalactitol," and provides a patent term that lasts until 2030. 

"This allowance represents our second U.S. patent. We believe that this key patent will provide another important anchor for DelMar's intellectual property portfolio," stated Jeffrey Bacha, DelMar's president and CEO. "This patent along with the previously granted patents and patent applications for VAL-083 are part of our continuing strategy to establish a broad portfolio of new patent claims to protect our intellectual property. Our patent applications, claim compositions and methods related to the use of VAL-083 and related compounds as well as methods of synthesis and quality controls for the manufacturing process of VAL-083."

About DelMar Pharmaceuticals

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI) and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action. DelMar's scientific presentations can be viewed on the company's website at www.delmarpharma.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com.

SOURCE DelMar Pharmaceuticals, Inc.